Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy
نویسندگان
چکیده
منابع مشابه
Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy
Melanoma is responsible for most skin cancer-related deaths and is one of the most common cancers diagnosed in young adults. In melanoma, tumors can become established by activation of the negative regulator of cytotoxic T lymphocytes (CTLs), CTL antigen-4 (CTLA-4). Ipilimumab blocks the interaction of CTLA-4 with CD80/CD86 and augments T-cell activation and proliferation. In electrochemotherap...
متن کاملImmuno-oncology safety education experience: Key lessons from ipilimumab (IPI)
Background IPI (Yervoy, Bristol-Myers Squibb) blocks cytotoxic Tlymphocyte antigen-4, a regulatory molecule on activated T cells. In March 2011, IPI, indicated for unresectable or metastatic melanoma (MEL), became the first immune checkpoint inhibitor approved by the US Food and Drug Administration (FDA). Early in development, severe and fatal immune-related adverse events (irAEs) emerged and w...
متن کاملElectrochemotherapy in veterinary oncology.
Electropermeabilization is a method that uses electric field pulses to induce an electrically mediated reorganization of the plasma membrane of cells. Electrochemotherapy combines local or systemic administration of chemotherapeutic drugs such as bleomycin or cisplatin that have poor membrane permeability with electropermeabilization by direct application of electric pulses to the tumors. Precl...
متن کاملCombination therapy of immunocytokines with ipilimumab: a cure for melanoma?
Although biological therapy has shown promising clinical responses in many cancers including metastatic melanoma, only a subset of patients has shown marked regression of lesions. In most patients, systemic administration of biological therapies with cytokines is associated with severe toxicities. Schwager et al., in this issue of Journal of Investigative Dermatology, have examined the role of ...
متن کاملCapecitabine plus docetaxel combination therapy
Health technology Two treatment options for patients with anthracycline-pretreated metastatic breast carcinoma were examined. The options were capecitabine (CAP) plus docetaxel (DOC) combination therapy and DOC alone. In the former (CAP+DOC), oral capecitabine (1,250 mg/m2 twice daily was given on days 1 14, followed by a 7-day rest period, with docetaxel (75 mg/m2) administered as a 1-hour int...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: OncoImmunology
سال: 2015
ISSN: 2162-402X
DOI: 10.1080/2162402x.2015.1008842